Navigation Links
Melt-Away Stent Works Well in Trial
Date:3/13/2008

Absorbed harmlessly in the body, it could replace traditional metal stents

THURSDAY, March 13 (HealthDay News) -- A polymer stent that is quietly absorbed by the body after it has done its job of keeping a coronary artery open has worked well in an international trial, researchers report.

The stent was successfully implanted in 29 of 31 attempts, the report said. In a one-year follow-up, none of the arteries in which the bio-absorbable stent had been implanted had closed again. One of the 30 people given the stent had a heart attack during that time, but no other adverse events were reported, according to the report in the March 15 issue of The Lancet.

A major clinical trial of the experimental stent is under way in several countries, said Karin Bauer, a spokeswoman for Abbott Laboratories, the company that developed the device. Plans for a U.S. trial are in the preliminary stages, she said.

"We currently are looking at the safety and feasibility of using the bio-absorbable stent platform in patients here," Bauer said. "Once we have completed the international trial, we will look at the feasibility of bringing such a trial to the United States, but we haven't made any decision as to when that might be."

The new stent has a backbone of lactic acid. It also is coated with everolimus, a drug that prevents formation of scar tissue.

Traditional stents are wire metal mesh tubes used to prop open an artery during angioplasty, a procedure done to clear blockages from the blood vessel.

An absorbable stent has many potential advantages, said Dr. Patrick W. Serruys, a professor of medicine and interventional cardiology at Erasmus Medical Center in Rotterdam, the Netherlands, one site of the international trial. Other sites are located in Denmark, Poland and New Zealand.

"The so-called restenosis process takes place in the first six months, so there is no need to have a permanent scaffolding device," Serruys explained. Restenosis is the reclosing of an artery, which can occur after a metal stent is implanted.

The polymer of which the Abbott stent is made breaks down to form carbon dioxide and water, "so you don't have a permanent foreign body in the blood vessel," he said. "That gives you more flexibility in the vessel. And some metallic stents are breaking, and the fracture of the metal creates some unpleasant reactions."

Because the polymer stent disappears, "many years later you are still able to work on the vessel," Serruys added. "You don't have a metallic cage that limits expansion of the vessel."

But there is a need for long-term follow-up of the experimental stent, he said, adding, "probably five or seven years down the road. Whenever you have a long-term follow-up, you can make a second attempt with the design. It will be a long process."

Still, Serruys said he was "impressed and amazed by the fact that the first attempt was so successful."

A second trial of a new version of the stent is in the planning stage, said study co-investigator Dr. John A. Ormiston, one of New Zealand's top interventional cardiologists and president of the Asia-Pacific Society of Interventional Cardiology. It will be done at the same sites as the first study, and will also have 30 stent recipients.

"There have been important design modifications," Ormiston said of the stent in the new trial. "The scaffold will be different so that it will be stronger. We think we might get even better results than we've had so far."

The trial could begin later this year. If it succeeds, it would be the prelude to a larger international trial that could lead to approval of the new stent for medical use, Ormiston said.

More information

Learn more about stents from the American Heart Association.



SOURCES: Patrick W. Serruys, M.D., professor, medicine and interventional cardiology, Erasmus Medical Center, Rotterdam, the Netherlands; Karin Bauer, spokeswoman, Abbott Laboratories, Abbott Park, Ill.; John Ormiston, MBChB, FRACP, FRACR, president, Asia-Pacific Society of Interventional Cardiology; March 15, 2008, The Lancet


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. The Lancet publishes first clinical trial data of a fully bioabsorbable drug-eluting stent
2. Combined stenting and photodynamic therapy improves survival in late stage liver cancer patients
3. Abbott Receives CE Mark for Smaller-Size XIENCE(TM) V Drug Eluting Stent
4. Experts Offer Clarity on Confusion Surrounding Stents
5. Study identifies which men are likely to have persistent prostate cancer
6. NIH report on intracranial stent points out need for upcoming large-scale clinical trial
7. Nfocus Neuromedical Receives CE Mark for the CardioVasc(TM) Stent-Graft and Delivery System
8. Half of patients undergoing cerebrovascular stent placement respond poorly to clopidogrel
9. Drug-Coated Stents Better Than Bare-Metal Ones in Complex Cases
10. Key Risk Factors for Suicide Consistent Across Globe
11. Study Finds Both Coated Stents Perform the Same
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ProVest Insurance Group, a family ... and Raleigh regions, is organizing an extended charity drive to benefit the family ... abnormality. , After struggling since birth with several health challenges, T.J. was later ...
(Date:10/13/2017)... ... October 13, 2017 , ... The ... to promote standards of excellence for the field of eating disorders, announces the ... – 25, 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. ...
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob Lowe, ... in a new episode of "Success Files," which is an award-winning educational program ... investigates each subject in-depth with passion and integrity. , Sciatica occurs when the ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
(Date:9/22/2017)... ROCKVILLE, Md. , Sept. 22, 2017  As ... by Republican Senators Bill Cassidy (R-LA) and ... Kalorama Information notes that the medical device industry is ... the medical device tax, the 2.3% excise tax on ... Act.  But they also want covered patients, increased visits ...
(Date:9/19/2017)... Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, ... tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek , PhD, ...
Breaking Medicine Technology: